Literature DB >> 1776679

A sensitive nonisotopic method for the determination of intracellular azidothymidine 5'-mono-, 5'-di-, and 5'-triphosphate.

T Toyoshima1, S Kimura, S Muramatsu, H Takahagi, K Shimada.   

Abstract

In order to analyze the efficacy of azidothymidine (AZT), it is important to know intracellular concentrations of AZT metabolites. However, it has been impossible to measure intracellular AZT 5'-monophosphate (AZT-MP), AZT 5'-diphosphate (AZT-DP), and AZT 5'-triphosphate (AZT-TP) without using isotopes. In the present study, we developed a new method to measure intracellular AZT metabolites without radiolabeled compounds. The method employed was a high-performance liquid chromatography (HPLC) system programmed for column switching technique, in which two columns were used: column 1 (TSK-G2000-SW, 300 x 7.5 mm) to preseparate AZT metabolites from major cell components, and column 2 (YMC-A-312-ODS, 150 x 6 mm) to determine the metabolites. The limit of detectability of this system was 3.3 pmol/injection. When MT-4 cells were incubated with various concentrations of AZT, intracellular concentrations of AZT-MP increased in parallel with extracellular AZT. Those of AZT-DP and AZT-TP, however, reached plateaus at 5 and 2 microM of AZT, respectively. In MT-4 and Molt-4 cells incubated with 5 microM AZT, concentrations of AZT-MP increased time dependently, while the AZT-DP/AZT-MP ratios decreased with time. These data suggest that high dose of AZT may not necessarily increase intracellular concentration of AZT-TP. The concentrations of AZT metabolites in peripheral blood mononuclear cells in a patient with AIDS and an asymptomatic carrier were measured; the concentrations were comparable to those in cultured cells. Quantitative analysis of intracellular AZT metabolites without the use of isotopes will increase safety and convenience of measurement, and take an effective step in studying pharmacokinetics of AZT in clinical materials.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1776679     DOI: 10.1016/0003-2697(91)90470-e

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  11 in total

1.  Simultaneous quantitation of the 5'-triphosphate metabolites of zidovudine, lamivudine, and stavudine in peripheral mononuclear blood cells of HIV infected patients by high-performance liquid chromatography tandem mass spectrometry.

Authors:  J D Moore; G Valette; A Darque; X J Zhou; J P Sommadossi
Journal:  J Am Soc Mass Spectrom       Date:  2000-12       Impact factor: 3.109

Review 2.  Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships.

Authors:  R M Hoetelmans; D M Burger; P L Meenhorst; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

3.  Quantitation of intracellular triphosphate of emtricitabine in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients.

Authors:  A Darque; G Valette; F Rousseau; L H Wang; J P Sommadossi; X J Zhou
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

4.  Quantitation of intracellular zidovudine phosphates by use of combined cartridge-radioimmunoassay methodology.

Authors:  B L Robbins; B H Waibel; A Fridland
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

5.  Intracellular nucleotides of (-)-2',3'-deoxy-3'-thiacytidine in peripheral blood mononuclear cells of a patient infected with human immunodeficiency virus.

Authors:  C Solas; Y F Li; M Y Xie; J P Sommadossi; X J Zhou
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

Review 6.  Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  Michelle I Wilde; Heather D Langtry
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

Review 7.  Intracellular phosphorylation of zidovudine (ZDV) and other nucleoside reverse transcriptase inhibitors (RTI) used for human immunodeficiency virus (HIV) infection.

Authors:  K Peter; J G Gambertoglio
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

8.  Comparison of rates of intracellular metabolism of zidovudine in human and primate peripheral blood mononuclear cells.

Authors:  M Qian; G Chandrasena; R J Ho; J D Unadkat
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

9.  Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography-radioimmunoassay procedure.

Authors:  J T Slusher; S K Kuwahara; F M Hamzeh; L D Lewis; D M Kornhauser; P S Lietman
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

10.  Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells.

Authors:  B L Robbins; J Rodman; C McDonald; R V Srinivas; P M Flynn; A Fridland
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.